A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with pegint

[Guest guest]

Hepatology. 2008 Feb 4 [Epub ahead of print]

A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in

combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3.

Ferenci P, Brunner H, Laferl H, Scherzer TM, Maieron A, Strasser M, Fischer G,

Hofer H, Bischof M, Stauber R, Gschwantler M, Steindl-Munda P, Staufer K,

Löschenberger K; Austrian Hepatitis Study Group.

Department of Internal Medicine III, Medical University, Vienna, Austria.

We compared the efficacy and tolerability of 24 weeks of treatment with

ribavirin 800 mg/day (group A) or 400 mg/day (group plus peginterferon

alfa-2a 180 mug/week in treatment-naive patients infected with hepatitis C virus

(HCV) genotype 2 or 3. A total of 97 of 141 patients randomized to group A

(68.8%, 95% confidence interval [CI] 60.5%-76.3%) and 90 of 141 patients

randomized to group B (63.8; 95% CI 55.3%-71.7%) achieved a sustained

virological response, defined as undetectable serum HCV RNA at the end of

untreated follow-up (week 48). Among patients infected with genotype 3, the rate

of sustained virological response was 67.5% (95% CI 58.4%-75.6%) in group A and

63.9% (95% CI 54.7%-72.4%) in group B, and among patients infected with genotype

2, the rate of sustained virological response was 77.8% (95% CI 54.2%-93.6%) in

group A and 55.6% (95% CI 38.4%-83.7%) in group B. Relapse rates in the 2

treatment groups were similar (17% in group A and 20% in group . The incidence

of adverse events, laboratory abnormalities, and dose reductions was similar in

the 2 treatment groups. Conclusion: The results suggest that when administered

for 24 weeks with peginterferon alfa-2a, ribavirin doses of 400 and 800 mg/day

produce equivalent outcomes in patients infected with HCV genotype 3.

(HEPATOLOGY 2008.).

PMID: 18454510 [PubMed - as supplied by publisher

_________________________________________________________________

Get Free (PRODUCT) RED™ Emoticons, Winks and Display Pics.

http://joinred.spaces.live.com?ocid=TXT_HMTG_prodredemoticons_052008

[Guest guest]

Hepatology. 2008 Feb 4 [Epub ahead of print]

A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in

combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3.

Ferenci P, Brunner H, Laferl H, Scherzer TM, Maieron A, Strasser M, Fischer G,

Hofer H, Bischof M, Stauber R, Gschwantler M, Steindl-Munda P, Staufer K,

Löschenberger K; Austrian Hepatitis Study Group.

Department of Internal Medicine III, Medical University, Vienna, Austria.

We compared the efficacy and tolerability of 24 weeks of treatment with

ribavirin 800 mg/day (group A) or 400 mg/day (group plus peginterferon

alfa-2a 180 mug/week in treatment-naive patients infected with hepatitis C virus

(HCV) genotype 2 or 3. A total of 97 of 141 patients randomized to group A

(68.8%, 95% confidence interval [CI] 60.5%-76.3%) and 90 of 141 patients

randomized to group B (63.8; 95% CI 55.3%-71.7%) achieved a sustained

virological response, defined as undetectable serum HCV RNA at the end of

untreated follow-up (week 48). Among patients infected with genotype 3, the rate

of sustained virological response was 67.5% (95% CI 58.4%-75.6%) in group A and

63.9% (95% CI 54.7%-72.4%) in group B, and among patients infected with genotype

2, the rate of sustained virological response was 77.8% (95% CI 54.2%-93.6%) in

group A and 55.6% (95% CI 38.4%-83.7%) in group B. Relapse rates in the 2

treatment groups were similar (17% in group A and 20% in group . The incidence

of adverse events, laboratory abnormalities, and dose reductions was similar in

the 2 treatment groups. Conclusion: The results suggest that when administered

for 24 weeks with peginterferon alfa-2a, ribavirin doses of 400 and 800 mg/day

produce equivalent outcomes in patients infected with HCV genotype 3.

(HEPATOLOGY 2008.).

PMID: 18454510 [PubMed - as supplied by publisher

_________________________________________________________________

Get Free (PRODUCT) RED™ Emoticons, Winks and Display Pics.

http://joinred.spaces.live.com?ocid=TXT_HMTG_prodredemoticons_052008

[Guest guest]

Hepatology. 2008 Feb 4 [Epub ahead of print]

A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in

combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3.

Ferenci P, Brunner H, Laferl H, Scherzer TM, Maieron A, Strasser M, Fischer G,

Hofer H, Bischof M, Stauber R, Gschwantler M, Steindl-Munda P, Staufer K,

Löschenberger K; Austrian Hepatitis Study Group.

Department of Internal Medicine III, Medical University, Vienna, Austria.

We compared the efficacy and tolerability of 24 weeks of treatment with

ribavirin 800 mg/day (group A) or 400 mg/day (group plus peginterferon

alfa-2a 180 mug/week in treatment-naive patients infected with hepatitis C virus

(HCV) genotype 2 or 3. A total of 97 of 141 patients randomized to group A

(68.8%, 95% confidence interval [CI] 60.5%-76.3%) and 90 of 141 patients

randomized to group B (63.8; 95% CI 55.3%-71.7%) achieved a sustained

virological response, defined as undetectable serum HCV RNA at the end of

untreated follow-up (week 48). Among patients infected with genotype 3, the rate

of sustained virological response was 67.5% (95% CI 58.4%-75.6%) in group A and

63.9% (95% CI 54.7%-72.4%) in group B, and among patients infected with genotype

2, the rate of sustained virological response was 77.8% (95% CI 54.2%-93.6%) in

group A and 55.6% (95% CI 38.4%-83.7%) in group B. Relapse rates in the 2

treatment groups were similar (17% in group A and 20% in group . The incidence

of adverse events, laboratory abnormalities, and dose reductions was similar in

the 2 treatment groups. Conclusion: The results suggest that when administered

for 24 weeks with peginterferon alfa-2a, ribavirin doses of 400 and 800 mg/day

produce equivalent outcomes in patients infected with HCV genotype 3.

(HEPATOLOGY 2008.).

PMID: 18454510 [PubMed - as supplied by publisher

_________________________________________________________________

Get Free (PRODUCT) RED™ Emoticons, Winks and Display Pics.

http://joinred.spaces.live.com?ocid=TXT_HMTG_prodredemoticons_052008

[Guest guest]

Hepatology. 2008 Feb 4 [Epub ahead of print]

A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in

combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3.

Ferenci P, Brunner H, Laferl H, Scherzer TM, Maieron A, Strasser M, Fischer G,

Hofer H, Bischof M, Stauber R, Gschwantler M, Steindl-Munda P, Staufer K,

Löschenberger K; Austrian Hepatitis Study Group.

Department of Internal Medicine III, Medical University, Vienna, Austria.

We compared the efficacy and tolerability of 24 weeks of treatment with

ribavirin 800 mg/day (group A) or 400 mg/day (group plus peginterferon

alfa-2a 180 mug/week in treatment-naive patients infected with hepatitis C virus

(HCV) genotype 2 or 3. A total of 97 of 141 patients randomized to group A

(68.8%, 95% confidence interval [CI] 60.5%-76.3%) and 90 of 141 patients

randomized to group B (63.8; 95% CI 55.3%-71.7%) achieved a sustained

virological response, defined as undetectable serum HCV RNA at the end of

untreated follow-up (week 48). Among patients infected with genotype 3, the rate

of sustained virological response was 67.5% (95% CI 58.4%-75.6%) in group A and

63.9% (95% CI 54.7%-72.4%) in group B, and among patients infected with genotype

2, the rate of sustained virological response was 77.8% (95% CI 54.2%-93.6%) in

group A and 55.6% (95% CI 38.4%-83.7%) in group B. Relapse rates in the 2

treatment groups were similar (17% in group A and 20% in group . The incidence

of adverse events, laboratory abnormalities, and dose reductions was similar in

the 2 treatment groups. Conclusion: The results suggest that when administered

for 24 weeks with peginterferon alfa-2a, ribavirin doses of 400 and 800 mg/day

produce equivalent outcomes in patients infected with HCV genotype 3.

(HEPATOLOGY 2008.).

PMID: 18454510 [PubMed - as supplied by publisher

_________________________________________________________________

Get Free (PRODUCT) RED™ Emoticons, Winks and Display Pics.

http://joinred.spaces.live.com?ocid=TXT_HMTG_prodredemoticons_052008